What You Should Know:
– GoodRx has unveiled two major initiatives to democratize access to GLP-1 medications: the launch of the GoodRx for Weight Loss telemedicine subscription and a new introductory cash price of $199 per month for Ozempic® and Wegovy® injection pens through a partnership with Novo Nordisk.
GoodRx for Weight Loss Telemedicine
GoodRx for Weight Loss, a direct-to-consumer telemedicine subscription is designed to simplify and manage every step of the GLP-1 treatment journey, from initial consultation to prescription fulfillment. The initiative aims to establish a higher standard for affordability and trust in weight loss care by connecting consumers only with FDA-approved GLP-1 medications, rejecting unproven compounded alternatives.
Key features of the new telemedicine subscription include:
- Virtual Consultations: Connects consumers with licensed healthcare providers to determine eligibility and prescribe FDA-approved GLP-1 treatments.
- Transparent Pricing: Ensures consumers know the cost of the medications upfront, without hidden fees.
- Fulfillment Options: Offers flexible fulfillment, including in-store pick-up nationwide for Wegovy or Zepbound® (tirzepatide), or convenient home delivery for the Zepbound vial formulation via LillyDirect.
- Ongoing Clinical Support: Provides continuous support to track progress, manage side effects, and adjust treatment as needed.
The telemedicine subscription is available for an introductory rate of $39 per month through January 2026, after which the standard price is $119 per month.
Delivering Real Savings on Ozempic and Wegovy
In a move to address the high cost of GLP-1s, GoodRx is collaborating with Novo Nordisk to offer unprecedented savings on two highly demanded medications. First-time GoodRx users who are self-paying can access Ozempic® (semaglutide) and Wegovy® (semaglutide) injection pens for an introductory price of just $199 per month.
- Eligibility: This introductory price applies to the two lowest doses (0.25 mg and 0.5 mg) and is valid for the first two fills.
- Ongoing Price: After the initial two months, patients will move to a new standard monthly price of $349 per month.
- Accessibility: These reduced prices make the treatments more affordable and accessible for eligible patients at nearly all pharmacies nationwide.
“GoodRx is scaling a consumer-first model for affordable GLP-1 treatment,” said Wendy Barnes, President and CEO of GoodRx. “We’re committed to connecting consumers with FDA-approved GLP-1 medications backed by science and safety, not compounded alternatives that fall short of those standards. By uniting nationwide pharmacy integration, home delivery capabilities, and transparent pricing in one seamless experience, GoodRx is creating a higher standard for affordability and trust in weight loss care.”
